drug_name event_name drug_id event_id drug_and_event_name
2 Glucose Disorder of lung 1560524 257907 Glucose & Disorder of lung 
## Chronograph ##

## Basic demographioc table##
1: DEC cohort n Percentage 2: Drug cohort n Percentage 3: Event cohort n Percentage 4: All drugs cohort n Percentage
Total 340 100 Total 1000 100 Total 1000 100 Total 1000 100
Sex gender = FEMALE 210 62 Sex gender = FEMALE 598 60 Sex gender = FEMALE 559 56 Sex gender = FEMALE 540 54
gender = MALE 130 38 gender = MALE 402 40 gender = MALE 441 44 gender = MALE 460 46
Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0
(20,30] 2 1 (20,30] 3 0 (20,30] 5 0 (20,30] 6 1
(30,40] 8 2 (30,40] 19 2 (30,40] 13 1 (30,40] 16 2
(40,50] 9 3 (40,50] 44 4 (40,50] 43 4 (40,50] 27 3
(50,60] 18 5 (50,60] 70 7 (50,60] 58 6 (50,60] 54 5
(60,70] 72 21 (60,70] 219 22 (60,70] 224 22 (60,70] 244 24
(70,80] 111 33 (70,80] 331 33 (70,80] 350 35 (70,80] 359 36
(80,90] 94 28 (80,90] 242 24 (80,90] 252 25 (80,90] 237 24
(90,110] 26 8 (90,110] 72 7 (90,110] 55 6 (90,110] 57 6
Median 77 IQR=(69, 84) Median 74 IQR=(68, 83) Median 74 IQR=(68, 82) Median 74 IQR=(68, 82) 
## Gender distribution ##
## DEC vs. drug ##
Characteristic % (n = 340) % (n = 1,000) Std.Diff Characteristic % (n = 340) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 4.1 2.1 -0.12
25 - 29 0.6 0.3 -0.04 Visual system disorder 52.4 35.9 -0.34
30 - 34 0.6 0.4 -0.03 Medical history: Cardiovascular disease
35 - 39 1.5 1.4 -0.01 Atrial fibrillation 44.4 30.1 -0.30
40 - 44 0.9 1.5 0.06 Cerebrovascular disease 17.4 10.8 -0.19
45 - 49 1.8 2.6 0.06 Coronary arteriosclerosis 50.6 30.8 -0.41
50 - 54 1.8 2.3 0.04 Heart disease 84.1 60.2 -0.55
55 - 59 2.6 4.4 0.10 Heart failure 44.7 25.7 -0.41
60 - 64 5.0 4.9 0.00 Ischemic heart disease 23.2 15.3 -0.20
65 - 69 12.9 14.3 0.04 Peripheral vascular disease 45.9 30.9 -0.31
70 - 74 16.5 18.5 0.05 Pulmonary embolism 6.8 2.5 -0.20
75 - 79 15.9 14.8 -0.03 Venous thrombosis 12.9 6.7 -0.21
80 - 84 17.9 15.0 -0.08 Medical history: Neoplasms
85 - 89 13.2 10.7 -0.08 Hematologic neoplasm 18.8 7.5 -0.34
90 - 94 4.1 5.0 0.04 Malignant lymphoma 8.8 2.8 -0.26
95 - 99 3.8 3.4 -0.02 Malignant neoplasm of anorectum 5.0 2.5 -0.13
100 - 104 0.9 0.5 -0.05 Malignant neoplastic disease 45.3 26.0 -0.41
Gender: female 61.8 59.8 -0.04 Malignant tumor of breast 8.2 3.6 -0.20
Medical history: General Malignant tumor of colon 13.2 4.9 -0.29
Acute respiratory disease 40.0 23.6 -0.36 Malignant tumor of urinary bladder 6.2 2.5 -0.18
Attention deficit hyperactivity disorder 0.3 0.3 0.00 Medication use
Chronic liver disease 6.2 2.1 -0.21 Agents acting on the renin-angiotensin system 66.2 72.2 0.13
Chronic obstructive lung disease 12.4 7.8 -0.15 Antibacterials for systemic use 51.5 55.5 0.08
Crohn’s disease 1.2 0.6 -0.06 Antidepressants 64.4 61.1 -0.07
Dementia 20.6 15.9 -0.12 Antiepileptics 36.2 36.7 0.01
Depressive disorder 18.2 11.4 -0.19 Antiinflammatory and antirheumatic products 32.9 36.1 0.07
Diabetes mellitus 74.4 56.4 -0.39 Antineoplastic agents 23.2 15.2 -0.21
Gastroesophageal reflux disease 27.1 16.2 -0.27 Antipsoriatics 1.2 1.0 -0.02
Gastrointestinal hemorrhage 12.6 6.4 -0.21 Antithrombotic agents 62.9 52.3 -0.22
Human immunodeficiency virus infection 0.3 0.7 0.06 Beta blocking agents 61.2 63.4 0.05
Hyperlipidemia 35.0 25.5 -0.21 Calcium channel blockers 49.1 56.6 0.15
Hypertensive disorder 8.8 5.0 -0.15 Diuretics 69.1 71.7 0.06
Lesion of liver 6.8 3.3 -0.16 Drugs for acid related disorders 56.5 46.8 -0.19
Obesity 12.1 6.6 -0.19 Drugs for obstructive airway diseases 46.8 35.3 -0.23
Osteoarthritis 54.7 38.6 -0.33 Drugs used in diabetes 60.3 63.9 0.07
Psoriasis 2.6 1.9 -0.05 Immunosuppressants 7.1 5.8 -0.05
Renal impairment 39.7 25.1 -0.32 Lipid modifying agents 67.9 74.1 0.14
Rheumatoid arthritis 8.8 7.5 -0.05 Opioids 42.1 35.3 -0.14
Schizophrenia 11.5 6.6 -0.17 Psycholeptics 61.2 53.7 -0.15
Ulcerative colitis 0.6 0.2 -0.06 Psychostimulants, agents used for adhd and nootropics 13.5 15.4 0.05
Urinary tract infectious disease 36.2 24.0 -0.27 
## Event vs. All ##
Characteristic % (n = 1,000) % (n = 1,000) Std.Diff Characteristic % (n = 1,000) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 3.1 1.0 -0.15
25 - 29 0.5 0.5 0.00 Visual system disorder 49.7 36.3 -0.27
30 - 34 0.2 0.6 0.06 Medical history: Cardiovascular disease
35 - 39 1.0 1.0 0.00 Atrial fibrillation 43.2 27.2 -0.34
40 - 44 1.2 1.1 -0.01 Cerebrovascular disease 14.8 9.9 -0.15
45 - 49 2.8 1.4 -0.10 Coronary arteriosclerosis 47.0 30.6 -0.34
50 - 54 1.8 2.3 0.04 Heart disease 82.9 56.5 -0.60
55 - 59 3.9 2.9 -0.06 Heart failure 40.1 23.4 -0.36
60 - 64 2.9 3.3 0.02 Ischemic heart disease 27.1 15.2 -0.29
65 - 69 14.6 16.2 0.04 Peripheral vascular disease 42.1 27.6 -0.31
70 - 74 21.5 21.4 0.00 Pulmonary embolism 4.1 2.5 -0.09
75 - 79 14.8 17.2 0.07 Venous thrombosis 10.9 6.9 -0.14
80 - 84 15.8 15.4 -0.01 Medical history: Neoplasms
85 - 89 11.7 9.4 -0.07 Hematologic neoplasm 15.3 7.8 -0.24
90 - 94 4.3 4.0 -0.02 Malignant lymphoma 7.8 3.9 -0.17
95 - 99 2.3 2.5 0.01 Malignant neoplasm of anorectum 3.6 1.2 -0.16
100 - 104 0.7 0.8 0.01 Malignant neoplastic disease 42.2 25.8 -0.35
Gender: female 55.9 54.0 -0.04 Malignant tumor of breast 6.3 4.1 -0.10
Medical history: General Malignant tumor of colon 7.5 3.4 -0.18
Acute respiratory disease 35.6 19.5 -0.37 Malignant tumor of urinary bladder 5.1 2.8 -0.12
Attention deficit hyperactivity disorder 0.6 0.3 -0.04 Medication use
Chronic liver disease 5.7 2.0 -0.19 Agents acting on the renin-angiotensin system 41.6 0 -1.19
Chronic obstructive lung disease 13.4 5.3 -0.28 Antibacterials for systemic use 39.4 0 -1.14
Crohn’s disease 0.7 0.6 -0.01 Antidepressants 38.2 0 -1.11
Dementia 20.8 12.5 -0.22 Antiepileptics 23.9 0 -0.79
Depressive disorder 9.6 8.4 -0.04 Antiinflammatory and antirheumatic products 23.8 0 -0.79
Diabetes mellitus 68.9 49.3 -0.41 Antineoplastic agents 14.5 0 -0.58
Gastroesophageal reflux disease 21.6 14.5 -0.19 Antipsoriatics 0.1 0 -0.04
Gastrointestinal hemorrhage 9.8 5.5 -0.16 Antithrombotic agents 39.3 0 -1.14
Human immunodeficiency virus infection 0.6 0.2 -0.06 Beta blocking agents 39.2 0 -1.14
Hyperlipidemia 35.9 26.7 -0.20 Calcium channel blockers 29.9 0 -0.92
Hypertensive disorder 6.6 3.1 -0.16 Diuretics 43.6 0 -1.24
Lesion of liver 6.8 3.2 -0.17 Drugs for acid related disorders 30.1 0 -0.93
Obesity 8.6 4.7 -0.16 Drugs for obstructive airway diseases 27.1 0 -0.86
Osteoarthritis 53.0 39.6 -0.27 Drugs used in diabetes 34.6 0 -1.03
Psoriasis 1.5 1.6 0.01 Immunosuppressants 4.3 0 -0.30
Renal impairment 36.7 21.1 -0.35 Lipid modifying agents 44.8 0 -1.27
Rheumatoid arthritis 10.5 5.2 -0.20 Opioids 27.2 0 -0.86
Schizophrenia 7.3 3.2 -0.18 Psycholeptics 40.1 0 -1.16
Ulcerative colitis 0.5 0.2 -0.05 Psychostimulants, agents used for adhd and nootropics 10.8 0 -0.49
Urinary tract infectious disease 31.2 19.1 -0.28 
## Drug vs. All ##
Characteristic % (n = 1,000) % (n = 1,000) Std.Diff Characteristic % (n = 1,000) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 3.1 1.0 -0.15
25 - 29 0.5 0.5 0.00 Visual system disorder 49.7 36.3 -0.27
30 - 34 0.2 0.6 0.06 Medical history: Cardiovascular disease
35 - 39 1.0 1.0 0.00 Atrial fibrillation 43.2 27.2 -0.34
40 - 44 1.2 1.1 -0.01 Cerebrovascular disease 14.8 9.9 -0.15
45 - 49 2.8 1.4 -0.10 Coronary arteriosclerosis 47.0 30.6 -0.34
50 - 54 1.8 2.3 0.04 Heart disease 82.9 56.5 -0.60
55 - 59 3.9 2.9 -0.06 Heart failure 40.1 23.4 -0.36
60 - 64 2.9 3.3 0.02 Ischemic heart disease 27.1 15.2 -0.29
65 - 69 14.6 16.2 0.04 Peripheral vascular disease 42.1 27.6 -0.31
70 - 74 21.5 21.4 0.00 Pulmonary embolism 4.1 2.5 -0.09
75 - 79 14.8 17.2 0.07 Venous thrombosis 10.9 6.9 -0.14
80 - 84 15.8 15.4 -0.01 Medical history: Neoplasms
85 - 89 11.7 9.4 -0.07 Hematologic neoplasm 15.3 7.8 -0.24
90 - 94 4.3 4.0 -0.02 Malignant lymphoma 7.8 3.9 -0.17
95 - 99 2.3 2.5 0.01 Malignant neoplasm of anorectum 3.6 1.2 -0.16
100 - 104 0.7 0.8 0.01 Malignant neoplastic disease 42.2 25.8 -0.35
Gender: female 55.9 54.0 -0.04 Malignant tumor of breast 6.3 4.1 -0.10
Medical history: General Malignant tumor of colon 7.5 3.4 -0.18
Acute respiratory disease 35.6 19.5 -0.37 Malignant tumor of urinary bladder 5.1 2.8 -0.12
Attention deficit hyperactivity disorder 0.6 0.3 -0.04 Medication use
Chronic liver disease 5.7 2.0 -0.19 Agents acting on the renin-angiotensin system 41.6 0 -1.19
Chronic obstructive lung disease 13.4 5.3 -0.28 Antibacterials for systemic use 39.4 0 -1.14
Crohn’s disease 0.7 0.6 -0.01 Antidepressants 38.2 0 -1.11
Dementia 20.8 12.5 -0.22 Antiepileptics 23.9 0 -0.79
Depressive disorder 9.6 8.4 -0.04 Antiinflammatory and antirheumatic products 23.8 0 -0.79
Diabetes mellitus 68.9 49.3 -0.41 Antineoplastic agents 14.5 0 -0.58
Gastroesophageal reflux disease 21.6 14.5 -0.19 Antipsoriatics 0.1 0 -0.04
Gastrointestinal hemorrhage 9.8 5.5 -0.16 Antithrombotic agents 39.3 0 -1.14
Human immunodeficiency virus infection 0.6 0.2 -0.06 Beta blocking agents 39.2 0 -1.14
Hyperlipidemia 35.9 26.7 -0.20 Calcium channel blockers 29.9 0 -0.92
Hypertensive disorder 6.6 3.1 -0.16 Diuretics 43.6 0 -1.24
Lesion of liver 6.8 3.2 -0.17 Drugs for acid related disorders 30.1 0 -0.93
Obesity 8.6 4.7 -0.16 Drugs for obstructive airway diseases 27.1 0 -0.86
Osteoarthritis 53.0 39.6 -0.27 Drugs used in diabetes 34.6 0 -1.03
Psoriasis 1.5 1.6 0.01 Immunosuppressants 4.3 0 -0.30
Renal impairment 36.7 21.1 -0.35 Lipid modifying agents 44.8 0 -1.27
Rheumatoid arthritis 10.5 5.2 -0.20 Opioids 27.2 0 -0.86
Schizophrenia 7.3 3.2 -0.18 Psycholeptics 40.1 0 -1.16
Ulcerative colitis 0.5 0.2 -0.05 Psychostimulants, agents used for adhd and nootropics 10.8 0 -0.49
Urinary tract infectious disease 31.2 19.1 -0.28 
## Top drugs and conditions for DEC ##
drugs_180_days n_180_days
antithrombotic agents 428
beta blocking agents 416
alimentary tract and metabolism 310
nervous system 305
cardiovascular system 300
blood and blood forming organs 275
all other therapeutic products 266
respiratory system 260
antiepileptics 246
analgesics 244
ophthalmologicals 244
sensory organs 244
antihistamines for systemic use 238
diuretics 235
systemic hormonal preparations, excl. sex hormones and insulins 234
psychoanaleptics 233
lipid modifying agents 231
lipid modifying agents, plain 231
agents acting on the renin-angiotensin system 225
antidepressants 219
hmg coa reductase inhibitors 210
psycholeptics 208
drugs used in diabetes 205
blood glucose lowering drugs, excl. insulins 201
stomatological preparations 200
cond_180_days n_180_days
heart disease 286
pain 282
inflammation of specific body systems 279
pain finding at anatomical site 277
arthropathy 273
inflammation of specific body organs 267
measurement finding outside reference range 265
vascular disorder 258
diabetes mellitus 253
soft tissue lesion 240
type 2 diabetes mellitus 234
pain of truncal structure 222
abnormal blood cell count 212
neoplastic disease 212
measurement finding below reference range 208
structural disorder of heart 207
cardiac arrhythmia 204
arteriosclerotic vascular disease 199
cytopenia 199
erythropenia 199
rbc count abnormal 199
rbc count low 199
hemoglobin level outside reference range 198
hemoglobin low 198
anemia 197